Exosomal miR-221-3p Derived from Bone Marrow Mesenchymal Stem Cells Alleviates Asthma Progression by Targeting FGF2 and Inhibiting the ERK1/2 Signaling Pathway

Figure 2

Exosomal miR-221-3p inhibited proliferation, migration, and ECM deposition in ASMCs. ASMCs were treated with TGF-β1 to induce a proliferation model and then incubated with BMSCs-derived exosomes alone or together with transfection with miR-221-3p inhibitor. (a) RT-qPCR was performed to measure the expression of miR-221-3p. (b) ASMC proliferation was evaluated by using the CCK-8 assay. (c), (d) ASMC migration was measured by using Transwell assay. (e)–(g) The protein expression of fibronectin and collagen III was analyzed by using western blot analysis. Data from at least three independent experiments were presented as mean ± SD .

(a)

(b)

(c)

(d)

(e)

(f)

(g)